Lord, Abbett & Co. LLC Krystal Biotech, Inc. Transaction History

Lord, Abbett & Co. LLC

  • $31.4 Billion
  • Q3 2024

A detailed history of Lord, Abbett & Co. LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Lord, Abbett & Co. LLC holds 284,159 shares of KRYS stock, worth $45.4 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares
284,159
Previous 284,159 -0.0%
Holding current value
$45.4 Million
Previous $51.7 Million -0.0%
% of portfolio
0.16%
Previous 0.17%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$174.7 - $213.66 $18.9 Million - $23.1 Million
-108,079 Reduced 27.55%
284,159 $51.7 Million
Q2 2024

Oct 07, 2024
SELL
$153.12 - $183.64 $15.3 Million - $18.4 Million
-99,994 Reduced 20.31%
392,238 $72 Million
Q2 2024

Aug 14, 2024
SELL
$153.12 - $183.64 $15.3 Million - $18.4 Million
-99,994 Reduced 20.31%
392,238 $72 Million
Q1 2024

Oct 07, 2024
SELL
$108.01 - $179.35 $13.6 Million - $22.6 Million
-126,226 Reduced 20.41%
492,232 $87.6 Million
Q1 2024

May 09, 2024
SELL
$108.01 - $179.35 $13.6 Million - $22.6 Million
-126,226 Reduced 20.41%
492,232 $87.6 Million
Q4 2023

Oct 07, 2024
SELL
$96.0 - $128.29 $5.07 Million - $6.78 Million
-52,853 Reduced 7.87%
618,458 $76.7 Million
Q4 2023

Feb 12, 2024
SELL
$96.0 - $128.29 $5.07 Million - $6.78 Million
-52,853 Reduced 7.87%
618,458 $76.7 Million
Q3 2023

Oct 07, 2024
SELL
$108.51 - $130.22 $18.6 Million - $22.3 Million
-171,337 Reduced 20.33%
671,311 $77.9 Million
Q3 2023

Nov 13, 2023
SELL
$108.51 - $130.22 $18.6 Million - $22.3 Million
-171,337 Reduced 20.33%
671,311 $77.9 Million
Q2 2023

Oct 07, 2024
SELL
$78.48 - $130.32 $9.31 Million - $15.5 Million
-118,594 Reduced 12.34%
842,648 $98.9 Million
Q2 2023

Aug 14, 2023
SELL
$78.48 - $130.32 $9.31 Million - $15.5 Million
-118,594 Reduced 12.34%
842,648 $98.9 Million
Q1 2023

Oct 07, 2024
SELL
$72.39 - $84.27 $22.9 Million - $26.7 Million
-316,780 Reduced 24.79%
961,242 $77 Million
Q1 2023

May 12, 2023
SELL
$72.39 - $84.27 $22.9 Million - $26.7 Million
-316,780 Reduced 24.79%
961,242 $77 Million
Q4 2022

Oct 07, 2024
BUY
$63.14 - $79.9 $55.9 Million - $70.8 Million
885,784 Added 225.83%
1,278,022 $101 Million
Q4 2022

Feb 10, 2023
BUY
$63.14 - $79.9 $4.17 Million - $5.28 Million
66,081 Added 5.45%
1,278,022 $101 Million
Q3 2022

Nov 14, 2022
BUY
$64.85 - $82.4 $6.12 Million - $7.78 Million
94,375 Added 8.44%
1,211,941 $84.5 Million
Q2 2022

Aug 12, 2022
SELL
$48.93 - $73.47 $3 Million - $4.5 Million
-61,247 Reduced 5.2%
1,117,566 $73.4 Million
Q1 2022

May 13, 2022
BUY
$51.99 - $72.11 $257,350 - $356,944
4,950 Added 0.42%
1,178,813 $78.4 Million
Q4 2021

Feb 11, 2022
BUY
$39.81 - $88.24 $4.25 Million - $9.42 Million
106,705 Added 10.0%
1,173,863 $82.1 Million
Q3 2021

Nov 09, 2021
SELL
$52.01 - $71.77 $6.47 Million - $8.93 Million
-124,422 Reduced 10.44%
1,067,158 $55.7 Million
Q2 2021

Aug 11, 2021
SELL
$62.14 - $81.82 $12.1 Million - $15.9 Million
-194,063 Reduced 14.01%
1,191,580 $81 Million
Q1 2021

May 11, 2021
BUY
$59.42 - $85.46 $75.5 Million - $109 Million
1,271,267 Added 1111.48%
1,385,643 $107 Million
Q4 2020

Feb 09, 2021
SELL
$40.64 - $61.38 $121,391 - $183,342
-2,987 Reduced 2.55%
114,376 $6.86 Million
Q3 2020

Nov 12, 2020
SELL
$37.76 - $48.49 $917,454 - $1.18 Million
-24,297 Reduced 17.15%
117,363 $5.05 Million
Q2 2020

Aug 14, 2020
SELL
$37.03 - $60.0 $2.77 Million - $4.5 Million
-74,932 Reduced 34.6%
141,660 $5.87 Million
Q1 2020

May 14, 2020
BUY
$35.02 - $65.64 $1.89 Million - $3.53 Million
53,851 Added 33.09%
216,592 $9.37 Million
Q4 2019

Feb 14, 2020
SELL
$33.17 - $65.23 $1.82 Million - $3.59 Million
-55,009 Reduced 25.26%
162,741 $9.01 Million
Q3 2019

Nov 14, 2019
BUY
$34.72 - $51.3 $7.56 Million - $11.2 Million
217,750 New
217,750 $7.56 Million

Others Institutions Holding KRYS

# of Institutions
303
Shares Held
24.3M
Call Options Held
483K
Put Options Held
364K
View Full List

About Krystal Biotech, Inc.

KRYS Quotes by TradingView
  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.1B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Lord, Abbett & Co. LLC Portfolio

Follow Lord, Abbett & Co. LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lord, Abbett & Co. LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email